Insider Selling: Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells 2,242 Shares of Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 13th. The stock was sold at an average price of $310.08, for a total value of $695,199.36. Following the sale, the executive vice president directly owned 24,848 shares of the company’s stock, valued at approximately $7,704,867.84. This trade represents a 8.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Pushkal Garg also recently made the following trade(s):

• On Monday, January 12th, Pushkal Garg sold 1,510 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $362.87, for a total value of $547,933.70.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY traded up $18.21 during midday trading on Tuesday, hitting $332.61. 1,516,365 shares of the company’s stock traded hands, compared to its average volume of 1,632,567. The firm has a fifty day moving average of $372.67 and a 200 day moving average of $424.73. The stock has a market capitalization of $44.11 billion, a price-to-earnings ratio of 194.51 and a beta of 0.35. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $0.82 earnings per share for the quarter, missing analysts’ consensus estimates of $1.43 by ($0.61). The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue for the quarter was up 84.9% compared to the same quarter last year. During the same period last year, the business posted ($0.65) earnings per share. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC dropped their price objective on Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Oppenheimer assumed coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They set an “outperform” rating and a $500.00 price objective for the company. Raymond James Financial restated an “outperform” rating and issued a $472.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Finally, Wells Fargo & Company lowered their target price on shares of Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Twenty-two investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $477.96.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Root Financial Partners LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter worth $25,000. Salomon & Ludwin LLC bought a new position in Alnylam Pharmaceuticals in the third quarter valued at about $27,000. HM Payson & Co. bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth about $27,000. Golden State Wealth Management LLC grew its position in shares of Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after buying an additional 36 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $29,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.